Series date: 
07/01/2021 - 7:00am CDT to 06/30/2022 - 4:00pm CDT

Please check the individual session for location or broadcast availability.  



Series Director

Frank Y. Lin, MD

Target Audience and Needs

Pediatric oncologists, geneticists, molecular and anatomic pathologists, surgeons, genetic counselors, medical trainees, and other healthcare professionals involved in the care of pediatric patients with cancer need to be regularly updated with the recent advances and guidelines in the field of pediatric oncology. The tumor board aims to increase knowledge of the learners using a multidisciplinary case approach, and encourages learners to implement the advances and guidelines in clinical practice to enhance the quality of patient care and outcomes.

Educational Methods

Educational methods will include case presentations and panel discussion.


At the conclusion of the sessions, the participants should be able to:

  • Apply the results of tumor and germline molecular testing to the diagnosis, prognosis, and treatment of pediatric cancer.
  • Demonstrate the expanding role of molecular diagnostics in formulating pediatric precision-oncology treatment strategies.
  • Use a multidisciplinary approach in interpreting results of molecular diagnostics.
  • Appraise the molecular tests currently available in pediatric oncology and recognize the limitations and risks of using them.


Participants may be asked to complete a session evaluation.

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Series Coordinator 

MacKenzie Harris

Series location: 
Texas Children's Hospital
6621 Fannin Street
Houston, TX 77030
United States